• Mashup Score: 0

    Columbia Engineering researchers announced today that they have developed the first stand-alone, conformable, fully organic bioelectronic device that can not only acquire and transmit neurophysiologic brain signals, but can also provide power for device operation.

    Tweet Tweets with this article
    • Researchers @CUSEAS have developed the first stand-alone, conformable, fully organic #bioelectronic #device that can not only acquire and transmit neurophysiologic #brain signals, but can provide power for device operation #transistors #bioelectricity https://t.co/Y8fEoo2LAt

  • Mashup Score: 0

    Bioelectronic Medicine is an emerging field that brings together multidisciplinary approaches with a common goal: the design of therapeutic treatments by the electrical modulation of the nervous system. While this field promises to solve a plethora of diseases by the use of engineered technology in materials and electronic devices, the contribution of purely neuroscientists, and specifically…

    Tweet Tweets with this article
    • Be a part of advancing the field of Bioelectronic Medicine providing fundamental mechanisms to inform and design new treatments. Open for submissions: https://t.co/g8XWf0OrvQ #Bioelectronic #Medicine #Bioengineering @UNAMINB @UNAM_MX @TranslationalIn @neurometab @AleGnzlzzz https://t.co/Q36XkTVeI8

  • Mashup Score: 0

    Galvani Bioelectronics has treated its first patient with a novel bioelectronic implant stimulating the splenic nerve as an experimental therapy for rheumatoid arthritis, according to a company press release.The company, a partnership between GlaxoSmithKline and Verily Life Sciences, a subsidiary of Google parent company Alphabet Inc., announced that the successful laparoscopic implantation and

    Tweet Tweets with this article
    • Stimulation of the #SplenicNerve via a #bioelectronic implant could help address "unmet needs" in #RheumatoidArthritis treatment, noted researchers, as first patients head into clinical trials https://t.co/JRk7qcjt2C